Search
Enmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigational[A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious
Copper histidinate
go.drugbank.com/drugs/DB32041Approvedin severe systemic copper deficiency. … [A275383,T903] In patients with the disease, defects in this transporter lead to the entrapment of copper in the intestinal lining and a subsequent inability to absorb it into the bloodstream, resulting
Temocapril
go.drugbank.com/drugs/DB08836InvestigationalTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. … Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Categories: Agents Acting on the Renin-Angiotensin SystemErgometrine
go.drugbank.com/drugs/DB01253ApprovedInvestigationalAn ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Synonyms: N-(α-(hydroxymethyl)ethyl)-D-lysergamide, N-(2-Hydroxy-1-methylethyl)-D-(+)-lysergamidePRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.
Categories: Compounds used in a research, industrial, or household settingElbimilast
go.drugbank.com/drugs/DB20663InvestigationalElbimilast is under investigation in clinical trial NCT00977886 (Safety and Pharmacokinetics of ELB353 in Healthy Men). Elbimilast has a monoisotopic molecular weight of 442.04 Da. … The usage of the INN stem '-milast' in the name indicates that Elbimilast is a Phosphodiesterase-4 (PDE4) inhibitor.
Bleselumab
go.drugbank.com/drugs/DB15253InvestigationalBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Odronextamab
go.drugbank.com/drugs/DB16684ApprovedInvestigationalThe partial clinical hold was later lifted in May 2021. … [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma
TU-100
go.drugbank.com/drugs/DB12467InvestigationalTU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.